(Reuters) -An explosion at a Los Angeles County Sheriff's Department training facility has killed three deputies, Fox News and local media reported on Friday, though officials have not yet confirmed any deaths.
A spokesperson for the Los Angeles Sheriff's Department confirmed that an explosion occurred at the Biscailuz Center Academy Training in East Los Angeles. The spokesperson said the cause was under investigation and that they were not yet ready to... (continue reading...)
Investing.com -- Invesco Capital Management (NYSE: IVZ) stock soared 13% Friday, reaching its highest intraday level since February, after the company filed a proxy statement with the Securities and Exchange Commission seeking to convert the Invesco QQQ Trust Series 1 into an open-ended fund.
The asset manager is asking shareholders to approve changing QQQ from its current unit investment trust structure to an open-ended fund, a move that could significantly alter... (continue reading...)
Investing.com -- Humana Inc (NYSE: HUM) stock fell as much as 7.5% before trimming losses to 4% following a court ruling against the health insurer in its Medicare bonus payment lawsuit. The decision also impacted other health insurers, with CVS Health (NYSE: CVS) and UnitedHealth Group (NYSE: UNH) shares declining 2%.
According to Bloomberg, a Texas district court ruled in favor of the government’s motion to dismiss Humana’s case, which sought to reverse cuts to its... (continue reading...)
Investing.com -- Artificial intelligence is driving a massive transformation across the technology sector, and its momentum is only beginning, according to Wedbush analysts led by Dan Ives.
In a note Friday, Wedbush projected that tech stocks are set for a strong second half of 2025, buoyed by a “very strong 2Q tech earnings season” and accelerating AI tailwinds across semiconductors, software, and enterprise applications.
“We have barely scratched the surface of this... (continue reading...)
Investing.com -- Jefferies initiated coverage on Stoke Therapeutics (NASDAQ: STOK) with a Buy rating given a better risk-reward profile ahead of late-stage data for its lead drug candidate targeting Dravet syndrome, a severe and rare form of childhood epilepsy.
The firm sees potential for zorevunersen, an antisense oligonucleotide (ASO) therapy, to show disease-modifying effects, an outcome that could position it for peak sales of $1 billion to $1.5 billion, with upside... (continue reading...)
More General News
View Older Stories-
BP to sell US onshore wind business to LS Power for undisclosed sum
-
OpenAI faces $700bn+ TAM by 2030: JPMorgan
-
Charles Schwab profit surges on trading boom, asset growth
-
Abbott upgraded after post-earnings selloff, hardware drag seen temporary
-
Morgan Stanley unpacks Tesla's edge: culture, talent, and strategy
-
Intel shares could squeeze higher during earnings, analyst says
-
HSBC says Apple needs more AI to sell more hardware
-
Sarepta shares tumble after report of patient death in early-stage trial
-
Chevron's $53 billion Hess acquisition cleared after arbitration ruling
-
3M sees smaller tariff hit on 2025 profit amid easing US-China trade tensions
-
S&P 500, Nasdaq flatline as Netflix weighs
-
Norfolk Southern gains after WSJ reports Union Pacific explores acquisition deal
-
Tesla picks Liberty General Insurance and Acko as insurance partners in India
-
'Squid Game' boosts Netflix quarter, company raises revenue guidance
-
US House passes crypto industry-backed market structure bill
-
Coke's shift to cane sugar would be expensive, hurt US farmers
-
’Feel the AGI’ - OpenAI launches ChatGPT Agent
-
Trump diagnosed with chronic venous insufficiency, remains healthy
-
GSK stock falls after FDA panel rejects blood cancer drug Blenrep
-
Deutsche Bank backs Visa, Mastercard amid fintech sector slump
-
What’s next for Renault stock after profit warning?
-
Waymo expands coverage in Austin, Texas, as robotaxi competition heats up
-
Jungheinrich stock tumbles after guidance cut
-
US import prices rise marginally in June
-
Trump-linked World Liberty Financial coin price could ’skyrocket’ says analyst
-
Boeing deliveries to remain firm after strong Q2: BofA
-
Jefferies downgrades SHAK, SBUX: Warns of stretched valuations, limited upside
-
Lucid stock soars after Uber partnership for autonomous robotaxi program
-
JP Morgan downgrades auto dealers on inventory buildup, tariff woes
-
Warsh calls for Fed overhaul, criticizes current leadership
-
US retail sales growth, steady job market bolster Fed's rate-cut delay
-
Uber to invest $300 million in EV maker Lucid as part of robotaxi deal
-
Barclays sees potential for Tesla stock to outperform. This is how
-
CSX, Norfolk Southern stocks rise on Union Pacific acquisition report
-
Archer-Daniels-Midland stock drops after Trump’s Coca-Cola sugar claim
-
Fifth Third Bancorp's quarterly profit rises on higher interest income
-
S&P 500 likely to get back on the straight and narrow
-
Micron stock falls after Goldman downgrades peer SK Hynix
-
Abbott flags over $1 billion hit in 2025 from tariffs, COVID test decline
-
Bristol Myers, Pfizer to sell blood thinner Eliquis directly to US patients
-
Tariff- and China-proof: Morgan Stanley finds value in this sector
-
OpenAI enlists Google Cloud to power ChatGPT - CNBC
-
Bill Gross urges investors to focus on Fed chair’s influence
-
KNDS owners explore IPO or stake sale amid defense sector interest
-
Nike downgraded by S&P as profitability slides, tariff pressures mount
-
Trump says firing Fed Chair Powell "highly unlikely" unless fraud found
-
XAI in talks to lease data center capacity in Saudi Arabia, Bloomberg News reports
-
BofA upgrades Rockwell to Buy amid US industrial reshoring
-
Microsoft, US national lab tap AI to speed up nuclear power permitting process
-
Jefferies on internet stocks: Own names offering 'peer-leading EBITDA growth'
